ダウンロード数: 386
タイトル: | 前立腺癌の分子標的治療(1) (第56回日本泌尿器科学会中部総会) |
その他のタイトル: | Molecular targeted therapy for prostate cancer |
著者: | 橋本, 良博 成山, 泰道 安藤, 亮介 岡田, 真介 戸澤, 啓一 郡, 健二郎 |
著者名の別形: | Hashimoto, Yoshihiro Naruyama, Hiromichi Ando, Ryousuke Okada, Shinsuke Tozawa, Keiichi Kohri, Kenjiro |
キーワード: | Molecular targeted therapy Prostate carcinoma Cell cycle regulator Steroid receptor co-activator |
発行日: | Jan-2008 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 54 |
号: | 1 |
開始ページ: | 57 |
終了ページ: | 61 |
抄録: | Androgen plays an important role in the growth of prostate cancer, but the molecular mechanism that underlies the development of resistance to anti-androgen therapy remains unknown. In this paper, we review the role of cell cycle regulators and steroid receptor co-activators for prostate cancer growth and survival. Cyclin E has been shown to increase the transactivation activity of the human androgen receptor and the proliferation of prostate cancer cells. On the other hand, p27 using an adenovirus vector was shown to reduce the size of tumors of human prostate cancer xenografts. Steroid receptor coactivator-3 (SRC-3) is often over-expressed in prostate cancers. Our results indicate that overexpression of SRC-3 can modulate the AKT (protein kinase B) signaling pathway and stimulate cell growth in prostate cancer. In contrast, down-regulation of SRC-3 expression by small interfering RNA suppresses cell growth. |
URI: | http://hdl.handle.net/2433/71563 |
PubMed ID: | 18260363 |
出現コレクション: | Vol.54 No.1 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。